Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2024 May 3;1(2):100008.
doi: 10.1016/j.bvth.2024.100008. eCollection 2024 Jun.

Real-world insights on the management of immune-mediated thrombotic thrombocytopenic purpura with caplacizumab

Daan Dierickx  1 , Thierry Connerotte  2 , Julie Dallemagne  3 , Ann De Becker  4 , Ine Moors  5 , Sylvia Snauwaert  6 , Anne Sonet  7 , Koen Theunissen  8 , Dimitri Breems  9 , Adrien De Voeght  10 , Aurélie Jaspers  11 , Catherine Lambert  12 , Bert Heyrman  9 , Joris Hautekiet  13 , Sofie Lyna  14 , Chantal Maertens  14 , Vanessa Delrieu  15
Affiliations

Real-world insights on the management of immune-mediated thrombotic thrombocytopenic purpura with caplacizumab

Daan Dierickx et al. Blood Vessel Thromb Hemost. .
No abstract available

PubMed Disclaimer

Conflict of interest statement

Conflict-of-interest disclosure: S.L. and C.M. are employees of Sanofi and may hold shares and/or stock options in the company. I.M. has received a travel grant from Sanofi for EHA 2022. D.B. has received travel and congress fees from Sanofi. A.D.V. has previously received fees from AbbVie. D.D. reports consultancy for Sanofi and honoraria from Sanofi. A.S. has received travel and congress fees from Sanofi. The remaining authors declare no competing financial interests.

Figures

Figure 1.
Figure 1.
Time to caplacizumab treatment and caplacizumab dosing information by first diagnosis/relapse subgroup. (A) Mean (SD) number of days between hospital admission and initiation of caplacizumab treatment. (B) Mean (SD) number of doses of caplacizumab per episode.
See this image and copyright information in PMC

References

    1. Kremer Hovinga JA, Coppo P, Lämmle B, Moake JL, Miyata T, Vanhoorelbeke K. Thrombotic thrombocytopenic purpura. Nat Rev Dis Primers. 2017;3 - PubMed
    1. Zheng XL, Vesely SK, Cataland SR, et al. ISTH guidelines for treatment of thrombotic thrombocytopenic purpura. J Thromb Haemost. 2020;18(10):2496–2502. - PMC - PubMed
    1. Cablivi (caplacizumab-yhdp) Ablynx NV; 2023. Summary of product characteristics.
    1. Völker LA, Kaufeld J, Miesbach W, et al. Real-world data confirm the effectiveness of caplacizumab in acquired thrombotic thrombocytopenic purpura. Blood Adv. 2020;4(13):3085–3092. - PMC - PubMed
    1. Coppo P, Bubenheim M, Azoulay E, et al. A regimen with caplacizumab, immunosuppression, and plasma exchange prevents unfavorable outcomes in immune-mediated TTP. Blood. 2021;137(6):733–742. - PMC - PubMed

LinkOut - more resources